These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

220 related articles for article (PubMed ID: 36048500)

  • 1. Impact of gender-affirming treatment on bone health in transgender and gender diverse youth.
    Ciancia S; Dubois V; Cools M
    Endocr Connect; 2022 Nov; 11(11):. PubMed ID: 36048500
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Bone Mineral Density in Transgender Adolescents Treated With Puberty Suppression and Subsequent Gender-Affirming Hormones.
    van der Loos MATC; Vlot MC; Klink DT; Hannema SE; den Heijer M; Wiepjes CM
    JAMA Pediatr; 2023 Dec; 177(12):1332-1341. PubMed ID: 37902760
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Development of Hip Bone Geometry During Gender-Affirming Hormone Therapy in Transgender Adolescents Resembles That of the Experienced Gender When Pubertal Suspension Is Started in Early Puberty.
    van der Loos MA; Hellinga I; Vlot MC; Klink DT; den Heijer M; Wiepjes CM
    J Bone Miner Res; 2021 May; 36(5):931-941. PubMed ID: 33507568
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Impact of Early Medical Treatment for Transgender Youth: Protocol for the Longitudinal, Observational Trans Youth Care Study.
    Olson-Kennedy J; Chan YM; Garofalo R; Spack N; Chen D; Clark L; Ehrensaft D; Hidalgo M; Tishelman A; Rosenthal S
    JMIR Res Protoc; 2019 Jul; 8(7):e14434. PubMed ID: 31290407
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Continuation of gender-affirming hormones in transgender people starting puberty suppression in adolescence: a cohort study in the Netherlands.
    van der Loos MATC; Hannema SE; Klink DT; den Heijer M; Wiepjes CM
    Lancet Child Adolesc Health; 2022 Dec; 6(12):869-875. PubMed ID: 36273487
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effect of pubertal suppression and cross-sex hormone therapy on bone turnover markers and bone mineral apparent density (BMAD) in transgender adolescents.
    Vlot MC; Klink DT; den Heijer M; Blankenstein MA; Rotteveel J; Heijboer AC
    Bone; 2017 Feb; 95():11-19. PubMed ID: 27845262
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Low Bone Mineral Density in Early Pubertal Transgender/Gender Diverse Youth: Findings From the Trans Youth Care Study.
    Lee JY; Finlayson C; Olson-Kennedy J; Garofalo R; Chan YM; Glidden DV; Rosenthal SM
    J Endocr Soc; 2020 Sep; 4(9):bvaa065. PubMed ID: 32832823
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pubertal Suppression, Bone Mass, and Body Composition in Youth With Gender Dysphoria.
    Navabi B; Tang K; Khatchadourian K; Lawson ML
    Pediatrics; 2021 Oct; 148(4):. PubMed ID: 34497118
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Association between pre-treatment IQ and educational achievement after gender-affirming treatment including puberty suppression in transgender adolescents.
    Arnoldussen M; Hooijman EC; Kreukels BP; de Vries AL
    Clin Child Psychol Psychiatry; 2022 Oct; 27(4):1069-1076. PubMed ID: 35638479
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Gender affirming medical care of transgender youth.
    Salas-Humara C; Sequeira GM; Rossi W; Dhar CP
    Curr Probl Pediatr Adolesc Health Care; 2019 Sep; 49(9):100683. PubMed ID: 31735692
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Bone Development in Transgender Adolescents Treated With GnRH Analogues and Subsequent Gender-Affirming Hormones.
    Schagen SEE; Wouters FM; Cohen-Kettenis PT; Gooren LJ; Hannema SE
    J Clin Endocrinol Metab; 2020 Dec; 105(12):e4252-63. PubMed ID: 32909025
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Testosterone Restores Body Composition, Bone Mass, and Bone Strength Following Early Puberty Suppression in a Mouse Model Mimicking the Clinical Strategy in Trans Boys.
    Dubois V; Ciancia S; Doms S; El Kharraz S; Sommers V; Kim NR; David K; Van Dijck J; Valle-Tenney R; Maes C; Antonio L; Decallonne B; Carmeliet G; Claessens F; Cools M; Vanderschueren D
    J Bone Miner Res; 2023 Oct; 38(10):1497-1508. PubMed ID: 37222072
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early puberty suppression and gender-affirming hormones do not alter final height in transgender adolescents.
    Ciancia S; Klink D; Craen M; Cools M
    Eur J Endocrinol; 2023 Sep; 189(3):396-401. PubMed ID: 37703317
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Youth and Caregiver Perspectives on Barriers to Gender-Affirming Health Care for Transgender Youth.
    Gridley SJ; Crouch JM; Evans Y; Eng W; Antoon E; Lyapustina M; Schimmel-Bristow A; Woodward J; Dundon K; Schaff R; McCarty C; Ahrens K; Breland DJ
    J Adolesc Health; 2016 Sep; 59(3):254-261. PubMed ID: 27235374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Puberty Assessment and Consideration of Gonadotropin-Releasing Hormone Agonists in Transgender and Gender-Diverse Youth.
    Lee JY
    Pediatr Ann; 2023 Dec; 52(12):e462-e466. PubMed ID: 38049185
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Puberty suppression in adolescents with gender dysphoria: an emerging issue with multiple implications.
    Betsi G; Goulia P; Sandhu S; Xekouki P
    Front Endocrinol (Lausanne); 2024; 15():1309904. PubMed ID: 38988996
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Bone Health in the Transgender and Gender Diverse Youth Population.
    Lee JY
    Curr Osteoporos Rep; 2023 Aug; 21(4):459-471. PubMed ID: 37395890
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Short-term outcomes of pubertal suppression in a selected cohort of 12 to 15 year old young people with persistent gender dysphoria in the UK.
    Carmichael P; Butler G; Masic U; Cole TJ; De Stavola BL; Davidson S; Skageberg EM; Khadr S; Viner RM
    PLoS One; 2021; 16(2):e0243894. PubMed ID: 33529227
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Review: Puberty blockers for transgender and gender diverse youth-a critical review of the literature.
    Rew L; Young CC; Monge M; Bogucka R
    Child Adolesc Ment Health; 2021 Feb; 26(1):3-14. PubMed ID: 33320999
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Determinants of bone mass accrual in transgender and gender diverse youth undergoing pubertal suppression therapy.
    Roberge S; Roberge T; Corathers S; Nasomyont N
    J Clin Densitom; 2024 Jun; 27(3):101505. PubMed ID: 38936233
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.